ImmunityBio’s stock is up after its off-the-shelf allogeneic CD19 chimeric antigen receptor natural killer cell therapy ...
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced updated efficacy and safety ...
GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE(R) natural killer (NK ...
GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative ...
Friday, ImmunityBio said the two complete responses are ongoing after seven and 15 months. The patients received four cycles ...
In order to reprogram readily available cells into specific immune cells that fight various diseases, one must know the ...
CAR T cells have made headlines for their ability to fight hematological cancers, but they have proven largely ineffective ...
A pair of patients with Waldenstrom’s non-Hodgkins lymphoma (NHL) remain in complete remission (CR) after 7 and 15 months ...
News-Medical.Net on MSN
Recent advances in CAR-NK cell therapy could revolutionze cancer treatment
Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, ...
Chimeric antigen receptor natural killer (CAR-NK) cell therapy is emerging as a promising next-generation immunotherapy with ...
US biotech ImmunityBio has reported two ongoing complete remissions lasting seven and 15 months in patients with Waldenstrom ...
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback